Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

盘前交易 09-29 07:01:08 EDT

3.96

+0.05

+1.15%

盘前3.98

+0.02+0.51%

06:45 EDT

最高4.00	最低3.68	成交量71.27万
今开3.89	昨收3.92	日振幅8.05%
总市值1.24亿	流通市值7,284万	总股本3,129万
成交额277.55万	换手率3.87%	流通股本1,839万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":3.96,"timestamp":1790625600000,"preClose":3.915,"halted":0,"volume":712696,"hourTrading":{"tag":"盘前","latestPrice":3.98,"preClose":3.96,"latestTime":"06:45 EDT","volume":149,"amount":593.02,"timestamp":1790678714147,"change":0.02,"changeRate":0.005051,"amplitude":0},"delay":0,"changeRate":0.011494252873563201,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"盘前交易","change":0.045,"latestTime":"09-29 07:01:08 EDT","open":3.89,"high":3.995,"low":3.68,"amount":2775531.5696736,"amplitude":0.08046,"askPrice":4.1,"askSize":1000,"bidPrice":3.49,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790688600000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":3.96,"preHourTrading":{"tag":"盘前","latestPrice":3.98,"preClose":3.96,"latestTime":"06:45 EDT","volume":149,"amount":593.02,"timestamp":1790678714147,"change":0.02,"changeRate":0.005051,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.91,"preClose":3.96,"latestTime":"19:30 EDT","volume":18134,"amount":71761.88,"timestamp":1790638204239,"change":-0.05,"changeRate":-0.012626,"amplitude":0.015152},"volumeRatio":0.8940743626947127,"impliedVol":3.1212,"impliedVolPercentile":0.94},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"2671929450","title":"Summit Therapeutics美股盘前涨超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671929450","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671929450?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:01","pubTimestamp":1790668879,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671265237","title":"据报道，Summit Therapeutics（SMMT）周一表示，英国制药公司阿斯利康（AstraZeneca，AZN","url":"https://stock-news.laohu8.com/highlight/detail?id=2671265237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671265237?lang=zh_cn&edition=full","pubTime":"2026-09-29 07:52","pubTimestamp":1790639529,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","SMMT","LENZ","GSKH","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669124044","title":"Viking Therapeutics Inc.收涨36%，创2024年2月份以来最佳单日表现。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669124044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669124044?lang=zh_cn&edition=full","pubTime":"2026-09-23 04:04","pubTimestamp":1790107466,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142648","title":"Viking Therapeutics涨超35%！减肥药传来捷报：给药频率减半仍维持97%减重","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142648","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669142648?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:50","pubTimestamp":1790085009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Viking Therapeutics周二盘前一度飙升近50%，此前这家生物科技公司宣布，其实验性肥胖症药物VK2735帮助患者在用药频率从每周一次降至每两周一次的情况下，仍维持了大部分减重成果。这一结果有望进一步增强VK2735在快速扩张的减肥药市场中的竞争地位。截至发稿，VKTX股价上涨近23%。今年以来，该股累计下跌约15%。据了解，VK2735是Viking的主要肥胖症候选药物，正在开发注射剂和口服剂两种剂型。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499522.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PJP","LENZ","TRUH","NVOH","NVOX","RSPH","BK4599","MEDI","BK4588","THNR","BK4585","FXH","NVOC","PINK","FHLC","XLVI","VKTX","NBDS","BK4539","BK4007","OZEM","CURE","BK4139","IYH"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2669198183","title":"Travere Therapeutics首席执行官Eric Dube将于2026年12月卸任。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669198183","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669198183?lang=zh_cn&edition=full","pubTime":"2026-09-22 04:06","pubTimestamp":1790021208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4139","BK4007","FFTY","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668964804","title":"百利天恒(688506.SH)子公司拟500万美元投资创新药企业Connexus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2668964804","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668964804?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:44","pubTimestamp":1789645459,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，为拓宽公司在除创新ADC药物研发平台，创新多特异性抗体药物研发平台，以及特异性增强双特异性抗体平台及创新ARC(核药)研发平台以外其他前沿技术赛道的布局，补充公司技术矩阵。公司全资子公司盘古资本拟以500万美元认购Connexus Therapeutics388.1万股A轮优先股股份，本次增资完成后，公司将持有Connexus 7.91%股权。Connexus是一家创新药企业，专注于肿瘤领域小分子药物的开发，其在研项目均处于临床前研发阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91194","BK4139","LNGR","IBBQ","688506","BK4007","MEDX","BK4539","BK0239","06978","LENZ","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667612838","title":"生物科技公司Electra Therapeutics(ETRA.US)IPO定价14-16美元/股 拟筹资3.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667612838","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667612838?lang=zh_cn&edition=full","pubTime":"2026-09-15 15:18","pubTimestamp":1789456715,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于开发靶向SIRP抗体、用于免疫疾病和癌症治疗的II/III期的生物科技公司Electra Therapeutics周一公布了首次公开募股的发行条款。Electra Therapeutics正在开发一类精准药物，靶向特定免疫细胞群体上表达的信号调节蛋白。Electra Therapeutics欲借今年生物科技板块IPO强劲表现的东风，为其处于临床阶段的免疫介导疾病和癌症药物管线筹集资金。汇编数据显示，今年美国生物科技与制药公司的IPO累计募资额已达68亿美元，平均加权回报率接近70%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","LENZ","XBI","BK4007","IEIH","IBBJ","BK4139","AGNG","SYNB","ETRA","BK4581","LNGR","HBImain","UUP","159837","UDN","BK4585","IPOS","BK4588","BK4539","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166014884","title":"新闻稿：Korsana Biosciences完成与Cyclerion Therapeutics的合并及此前公布的3.8亿美元私募融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1166014884","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166014884?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:07","pubTimestamp":1788898066,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年9月8日——致力于开发创新疗法以减轻神经退行性疾病负担的生物技术公司Korsana Biosciences, Inc.今日宣布，此前公布的与Cyclerion Therapeutics, Inc.的合并已正式完成。合并后的公司将以Korsana Biosciences, Inc.的名义运营，其股票预计于2026年9月9日开始在纳斯达克资本市场交易，代码为\"KRSA\"。根据此前披露的合并协议条款，每股Korsana普通股转换为获得约0.2074股合并公司普通股的权利，该比例已根据合并前即刻生效的Cyclerion Therapeutics普通股1比7反向股票分割进行调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4588","TM","BK4555","BK4585","BK4099","BK4139","03160","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144058806","title":"Acrivon Therapeutics任命Michaela Levin博士担任首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1144058806","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144058806?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:35","pubTimestamp":1788179734,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年8月31日—— Acrivon Therapeutics, Inc.，一家临床阶段、致力于发现和开发精准药物的生物技术公司，利用其专有的Generative Phosphoproteomics AP3平台进行理性药物设计和预测性临床开发，今日宣布任命Michaela Levin博士为首席商务官，自2026年8月31日起生效。\"在公司发展的关键阶段加入Acrivon，我倍感振奋，\"Levin博士表示。本新闻稿中的前瞻性声明仅截至发布之日作出，除适用法律要求外，Acrivon不承担更新此类信息的义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ACRV","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663026876","title":"【新股IPO】Frontera Therapeutics向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2663026876","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663026876?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:56","pubTimestamp":1788141419,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所8月28日披露，Frontera Therapeutics向港交所主板提交上市申请，瑞银集团、海通国际为联席保荐人。公司于2019年注册成立，是一家临床阶段基因疗法公司，致力于自主开发重组腺相关病毒基因疗法。公司的管线尤其专注于眼科及心血管疾病。截至最后实际可行日期，公司的产品管线包括六款自主开发的rAAV基因治疗候选药物。自注册成立以来，公司一直由独立于创始股东的管理团队运营。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989983","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","KCE","FRHC","LENZ","BK4007","HEXmain","REDS","BK4539","BK4139","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663114360","title":"Electra Therapeutics(ETRA.US)递交美股IPO申请，借生物科技上市热潮推进免疫疾病与癌症新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2663114360","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663114360?lang=zh_cn&edition=full","pubTime":"2026-08-29 11:05","pubTimestamp":1787972713,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物科技公司Electra Therapeutics Inc.已正式递交首次公开募股申请，欲借今年生物科技板块IPO强劲表现的东风，为其处于临床阶段的免疫介导疾病和癌症药物管线筹集资金。截至今年6月30日，公司持有现金及现金等价物约9770万美元。其中，脱发治疗药物研发商Veradermics Inc.自2月上市以来股价飙升476%，领跑该板块。Electra此次IPO的主承销商包括杰富瑞金融集团、多伦多道明银行、Evercore Inc.和Cantor Fitzgerald。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCE","159837","BK4588","IPOS","BK4127","XBI","MEDX","REDS","IBBJ","GDOC","BK4139","LNGR","AGNG","BK4007","SYNB","LENZ","BK4581","HBImain","BK4539","BK4585","FRHC","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663011439","title":"Electra Therapeutics(ETRA.US)递交美股IPO申请，借生物科技上市热潮推进免疫疾病与癌症新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2663011439","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663011439?lang=zh_cn&edition=full","pubTime":"2026-08-29 11:05","pubTimestamp":1787972713,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KCE","BK4588","IPOS","BK4127","XBI","MEDX","REDS","IBBJ","GDOC","BK4139","LNGR","AGNG","BK4007","SYNB","LENZ","BK4581","BK4539","BK4585","FRHC","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662712415","title":"Spyre Therapeutics股价下跌13.8%，因该公司试验药物未能达到类风湿性关节炎单药治疗开发的预设门槛。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662712415","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662712415?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:35","pubTimestamp":1787751332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113424300","title":"美股开盘 | 三大指数集体低开，Meta逆势涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113424300","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113424300?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:30","pubTimestamp":1787751030,"startTime":"0","endTime":"0","summary":"8月26日，美股三大指数集体低开，道琼斯指数跌0.01%，标普500指数跌0.13%，纳斯达克综合指数跌0.22%。Meta涨超3%，与美国多个州同意就青少年社交媒体危害案达成和解；Summit Therapeutics涨超10%，核心候选药物依沃西单抗III期试验数据积极；爱芬奇涨超20%，Q2业绩超市场预期，同步上调全年业绩指引；先科电子涨超5%，Q2业绩远超市场预期，Q3业绩指引强劲。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655073.USD","LU2360032135.SGD","QQQM","LU0203345920.USD","LU0210536198.USD","IE00BK4W5L77.USD","LU0225283273.USD","LU1119994496.HKD","LU0109392836.USD","LU1670710588.SGD","LU2106854487.HKD","XLC","LU1804176565.USD","BK4077","LU0738911758.USD","IE00BJTD4V19.USD","LU1670711040.USD","IE00B7SZLL34.SGD","IE00BFSS8Q28.SGD","LU0943347566.SGD","LU2552382058.USD","LU2420271590.USD","IVV","LU0079474960.USD","LU1267930730.SGD","LU0080751232.USD","DDM","03034","UPRO","LU1551013342.USD","IE000YTNTUN2.SGD","LU0198837287.USD","IE0002270589.USD","SMETAmain","LU0444973449.USD","LU0784385840.USD","LU1732800096.USD","XDAT","LU2463028550.USD","LU1564329032.USD",".DJI","LU1074936037.SGD","SPDN","LU0106261372.USD","BK4141","LU0787776722.HKD","LU0211327993.USD","LU1670710661.SGD","LU1979441026.SGD",".SPX","QLD","IE00BMPRXN33.USD","LU1697837992.HKD","IE0000B7K699.USD","BK4585","IE00B7KXQ091.USD","LU1242518857.USD","ANF","IE00B4YYXB79.USD","LU1852331112.SGD","LU1718418525.SGD","SG9999017495.SGD","IE000BZT7R73.USD","IE000KEQY171.SGD","LU0265550359.USD","LU1571399168.USD","LU1732799900.SGD","IE0009G5SDU7.USD","LU1992135399.USD","LU2403377893.USD","LU2860962120.EUR","LU0979878070.USD","IE00BMPRXR70.SGD","NJUL","IE00B3SWFQ91.USD",".IXIC","LU2764263203.CNY","LU1429558221.USD","LU2461242641.AUD","SPXS","LU0234570918.USD","LU1496350502.SGD","LU1564329115.USD","IE00B1XK9C88.USD","QQQX","LU0912757837.SGD","LU2456880835.USD","LU2417539215.USD","LU1242518931.SGD","SG9999015952.SGD","LU2896262040.SGD","LU1670711123.USD","LU1935042488.USD","LU1803068979.SGD","LU2746668974.SGD","LU2065169927.USD","VOO","LU0353189763.USD","BK4539","LU0353189680.USD","LU2552382132.HKD","LU0417517546.SGD","SGXZ80539844.SGD","LU2236285917.USD","LU2265009873.SGD","RSPC","SG9999004303.SGD","LENZ","LU0068578508.USD","LU2054465674.USD","YSPY","GB00B4QBRK32.GBP","LU0256863811.USD","LU0070217475.USD","LU2023250330.USD","LU0354030511.USD","LU0552385451.USD","LU0823421333.USD","VOX","LU2361044949.HKD","IE00B5949003.HKD","LU1564329461.SGD","METU","SPYM","LU0061474705.USD","LU2430703251.USD","IE0034235303.USD","LU2543165471.USD","07568","LU2458330243.SGD","LU1066051498.USD","BK4524","IE00BQXX3F31.USD","LU2213496289.HKD","LU0210528500.USD","LU2133065610.SGD","LU0640476718.USD","LU2381873111.SGD","07266","LU1116320901.HKD","LU0187121727.USD","SGXZ81514606.USD","NAPR","SG9999015986.USD","LU2360106780.USD","LU0256863902.USD","LU2404859741.USD","LU0784384876.USD","IE00B19Z8X17.USD","LU1003077747.HKD","LU2505996509.AUD","LU0308772762.SGD","LU2168564495.EUR","LU0109391861.USD","LU0056508442.USD","HK0000304805.HKD","LU0096362180.USD","LU1839511570.USD","LU1791710400.SGD","LU2272731600.USD","LU0154236417.USD","LU1642822529.SGD","LU2487616109.SGD","LU0672654240.SGD","LU0267386448.USD","GB00BDT5M118.USD","LU2237957902.USD","IE00B19Z8W00.USD","LU1699723380.USD","LU1674673691.USD","07522","SGXZ23171101.USD","LU2764262908.HKD","LU0985489474.SGD","LU0444971666.USD","02834","LU2462591350.SGD","NULC","METG","SPYQ","LU1935042215.USD","UDOW","IE0005OL40V9.USD","LU0354030438.USD","LU0072462426.USD","TRUC","SPXL","IE00BJLML261.HKD","LU0823434740.USD","IE00B19Z3581.USD","LU2097829019.USD","LU2023250504.SGD","LU0310799852.SGD","BK4588","LU1366192091.USD","LU0323591593.USD","SGXZ31699556.SGD","SSO","LU1235294995.USD","DXD","SG9999001077.SGD","LU0011850046.USD","SPUU","LU1935042991.SGD","LU2756315664.SGD","LU2462157665.USD","IE000MB6IJN5.SGD","LU0949170772.SGD","FBY","LU1868837136.USD","DIA","DMAX","FBL","LU0149725797.USD","TQQQ","FBYY","LU0957808578.USD","LU1815336091.USD","SG9999002232.USD","LU0061474960.USD","BK4592","IE00B19Z3B42.SGD","METQ","LU0642271901.SGD","METW","LU2125154935.USD","LU2247934214.USD","LU2272731865.HKD","BK4007","SMTC","LU1868836914.USD","LU1267930490.SGD","IE00BQXX3C00.GBP","LU1814569148.SGD","IE00B4JS1V06.HKD","LU1059921491.USD","SPYH","HK0000914660.USD","IE000WAW04H5.SGD","LU0072461881.USD","LU0661504455.SGD","LU0476273544.USD","LU0265550946.USD","LU1868836591.USD","LU1992135472.HKD","IE00BJTD4N35.SGD","LU1670627923.USD","LU2602419157.SGD","03086","LU0157215616.USD","LU1868837300.USD","IE00B19Z9505.USD","LU0211331839.USD","IE00BK4W5M84.HKD","LU2357305700.SGD","LU2063271972.USD","LU1720051108.HKD","BK4507","LU0433182093.SGD","LU1815336760.USD","LU0820561818.USD","LU1935043023.USD","LU0795875169.SGD","LU0708995401.HKD","LU0784385170.HKD","LU0203347892.USD","LU1868836757.USD","LU1316542783.SGD","LU1232071149.USD","LU0882574139.USD","LU2322448957.HKD","QQQ","LU2168564065.EUR","SMAX","SMTG","LU0786609619.USD","LU2552382215.SGD","IE0001KFT4U8.USD","LU1823568750.SGD","LU1988902786.USD","SG9999002224.SGD","IE0003U64NQ7.SGD","LU0348723411.USD","LU1153585028.USD","LU0314104364.USD","LU1280957306.USD","LU0726765562.USD","LU0210533765.USD","LU0205194284.USD","IE00BMPRXQ63.HKD","LU1201861249.SGD","LU0566484027.USD","LU1670628061.USD","LU1674673428.USD","LU2756315318.SGD","LU1974910355.USD","PSQ","LU1861558580.USD","LU1778281490.HKD","LU2720916845.USD","LU0689472784.USD","QTWO","GXPC","IE000ITXATA3.USD","LU0211328371.USD","OGIG","SOCL","LU1046421795.USD","IE0004445015.USD","LU2168563687.JPY","LU1564329628.SGD","SG9999014914.USD","SQQQ","IE00BFSS7M15.SGD","SG9999014906.USD","GB00B4LPDJ14.GBP","LU2430703178.SGD","LU2065170008.USD","LU0106261612.USD","LU2430703095.HKD","LU0957791311.USD","LU0648001328.SGD","GAMR","LU0127658192.USD","IE00B775H168.HKD","IE00BJJMRX11.SGD","LU1069344957.HKD","LU2237957811.SGD","IE00BN29S564.USD","IE000W1ABFV2.USD","LU2326559502.SGD","09086","LU0170899867.USD","LU0466842654.USD","LU2458330169.SGD","LU0345769631.USD","LU0528227936.USD","IE000SO60NU8.SGD","LU2168564222.USD","FBX","LU0208291251.USD","LU0553294199.USD","NOCT","LU0719512351.SGD","QID","LU2488822045.USD","LU1084165304.USD","LU2250418816.HKD","LU1917777945.USD","LU2505996681.GBP","LU1935043536.SGD","LU2317271919.USD","METD","09834","LU0820561909.HKD","LU0878866978.SGD","SGXZ99366536.SGD","LU2023250843.SGD","LU0061475181.USD","SG9999014898.SGD","LU0097036916.USD","LU0130102774.USD","IE0004445239.USD","LU0823421416.USD","HK0000914686.HKD","LU2264538146.SGD","LTL","LU0690374615.EUR","LU1914381329.SGD","LU1127390331.HKD","MMAX","LU0006306889.USD","LU0985320562.USD","GPIQ","SG9999018865.SGD","LU0316494557.USD","LU0345769128.USD","LU1064131342.USD","BK4543","LU0077335932.USD","HIBL","LU0690374961.EUR","LU1366333091.USD","LU1551013425.SGD","BK4094","IE00BKDWB100.SGD","LU1791710582.SGD","SPYU","BK4587","LU1489326972.SGD","LU0276348264.USD","LU0012050646.USD","LU0174119429.USD","LU2404859667.USD","LU0082616367.USD","LU1629891620.HKD","LU0788109477.HKD","LU0683600562.USD","IE000F7OJYX1.SGD","IE00BWXC8680.SGD","LU2087621335.USD","LU2361044865.SGD","LU1435385759.SGD","LU0162691827.USD","LU1066053197.SGD","LU0889565833.HKD","NJAN","SDS","LU1559883803.SGD","LU2087625088.SGD","LU2244417387.USD","LU0823434583.USD","LU1301847155.USD","LU1261432733.SGD","LU2746668461.USD","SH","LU2242650005.HKD","LU1861559042.SGD","LU2347655156.SGD","LU2361045086.USD","IE0034235188.USD","LU0757428866.USD","IE0009356076.USD","LU1720051017.SGD","LU0980610538.SGD","SPY","LU2592432038.USD","LU1035775433.USD","YMmain","SG9999015978.USD","LU2125154778.USD","LU1145028129.USD","LU0096364046.USD","LU0795875086.SGD","SG9999018857.SGD","LU2473716301.USD","SG9999014880.SGD","07261","LU0053666078.USD","LU0234572021.USD","SGXZ51526630.SGD","LU2272731782.SGD","IE00B1BXHZ80.USD","LU2065171311.SGD","IE00BJJMRY28.SGD","LU0205193047.USD","IE00BQXX3D17.EUR","QDEC","DOG","SG9999015945.SGD","LU0545039389.USD","NDX","LU2168564149.EUR","SMMT","FCOM","LU0784383803.USD","META","LU1116320737.USD","LU2065171402.SGD","LU0215105999.USD","LU0724617625.USD","LU0070302665.USD","BK4023","SPXU","TQQY","LU0133085943.USD","SDOW","LU0820562030.AUD","LU0320765059.SGD","LU0203201768.USD","LU0320765489.SGD","LU2322448791.USD","LU1548497426.USD","BK4139","LU0964807845.USD","03455","LU0949170426.SGD","HK0000304797.USD","LU0203202063.USD","LU1815333072.USD","METV","QMAR","LU2764263039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662716390","title":"Summit Therapeutics美股盘前涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662716390","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662716390?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:52","pubTimestamp":1787745128,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185070568","title":"新闻稿：Oruka Therapeutics任命Todd Edwards为首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1185070568","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185070568?lang=zh_cn&edition=full","pubTime":"2026-08-25 04:04","pubTimestamp":1787601874,"startTime":"0","endTime":"0","summary":"加州门洛帕克，2026年8月24日——Oruka Therapeutics, Inc.是一家临床阶段的生物技术公司，致力于开发新型生物制剂，旨在为斑块状银屑病和化脓性汗腺炎等慢性皮肤病的治疗树立新标准。该公司今日宣布，任命Todd Edwards为首席商务官，自2026年8月24日起生效。他此前在Arcutis Biotherapeutics, Inc.担任执行副总裁兼首席商务官，期间领导了ZORYVE产品线的转型——重建了银屑病商业组织，推出了特应性皮炎和脂溢性皮炎的新适应症，并实现了持续的收入增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4539","LU0889565916.HKD","LENZ","LU0320765992.SGD","BK4007","BK4232","BK4139","ORKA","BK4022","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661290857","title":"据美国证券交易委员会披露文件显示，OS Therapeutics公司计划通过杰富瑞集团发售最高规模为7500万美元的普通","url":"https://stock-news.laohu8.com/highlight/detail?id=2661290857","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661290857?lang=zh_cn&edition=full","pubTime":"2026-08-22 04:43","pubTimestamp":1787345036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4559","SOLC","JEF","LENZ","BK4139","BK4539","BK4127","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164486796","title":"Lenz Therapeutics遭美银全球研究下调评级：从“买入”降至“中性”，目标价从31美元大幅下调至7美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164486796","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164486796?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:10","pubTimestamp":1786619414,"startTime":"0","endTime":"0","summary":"美银全球研究机构近日对Lenz Therapeutics作出了关键性调整。该机构将这家公司的股票评级从“买入”直接下调至“中性”。这并非孤立的举措，同一时间，它们还彻底修正了其价格预期，目标价已从先前的31美元大幅削减至7美元，降幅十分显著。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931704","title":"Tenax Therapeutics股价暴跌87.2%，此前该公司的心脏药物在后期研究中未达到主要目标。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931704","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658931704?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:31","pubTimestamp":1786368718,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193258586","title":"新闻稿：Ernexa Therapeutics 引入资深生物技术高管 David Polinsky 加入董事会，为临床阶段冲刺蓄力","url":"https://stock-news.laohu8.com/highlight/detail?id=1193258586","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193258586?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:09","pubTimestamp":1786367399,"startTime":"0","endTime":"0","summary":"此次任命正值公司关键转折点，进一步强化了其领导团队——Ernexa 正全力推进其核心项目 ERNA-101，计划于2026年第三季度提交新药临床试验申请，并在第四季度启动首项一期临床研究。马萨诸塞州剑桥市，2026年8月10日——Ernexa Therapeutics，一家致力于开发创新细胞疗法以治疗晚期癌症和自身免疫性疾病的行业先锋，今日宣布任命 David Polinsky 为其董事会成员。“我们正步入 Ernexa 历史上最为重要的时期之一，”Ernexa Therapeutics 总裁兼首席执行官 Sanjeev Luther 表示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IND","BK4139","IBB","LENZ","RFL","XBI","BK4588","BK4539","SYNB","BK4233","BK4205","BBP","ERNA","BK4007","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0294},{"period":"1month","weight":-0.225},{"period":"3month","weight":-0.3028},{"period":"6month","weight":-0.5765},{"period":"1year","weight":-0.9058},{"period":"ytd","weight":-0.7525}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.0252},{"period":"6month","weight":0.1684},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1227}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.033083},{"month":8,"riseRate":0.333333,"avgChangeRate":0.01095},{"month":9,"riseRate":0.5,"avgChangeRate":-0.017591},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}